Introduction
Translational research combines basic and clinical science to promote knowledge in prevention, diagnosis, and therapyo f human disease. The final goal is the promotion of qualityo f life and societyw ell-being. [1] Likewise, at ranslational chemistry approachw ould providet he initial foundation to understand human diseases at the molecularl evel.U sing chemical tools, [2] chemists can connectm olecular information and biological functiono rd ysfunction. This methodology has been used in the areas of medicinal chemistry,c hemical biology,a nd biochemistry.A dditionally,i ti sp ossible to link molecular information and to establish physicochemical modelst ou nderstand complex systems, such as those observedi nh uman diseases. This last strategy is commonly used in physicalorganic chemistry research, and as Prof. GeorgeW hitesides recently defined, "it is not really about physical chemistry, organic chemistry,o r even chemistry.I tis as trategy for the designo fp rograms in experimentals cientific research, which offers ag eneral, and remarkably versatile, method for tackling complex problems." [3] From the perspective of the aforementioned chemical disciplines and the idea to translate this knowledge into biomedical research, we embarked recently on translational chemistry research to shed light on the complicated immunological disorders relatedt og luten. Herein, we review these diseases from a clinicalp oint of view to the up-to-nowm olecular and supramolecular understanding.
Gluten-Related Disorders:The Clinical Point of View
Gluten-related disorders are complex immune-mediated diseases that affect around 1-7 %o ft he general population. [4] They are nameda ccording to clinical symptoms and type of immunological response, for example, wheat allergy,c eliac disease (CD), gluten ataxia,d ermatitis herpetiformis, and nonceliac gluten sensitivity (NCGS) (Figure 1 ). It is assumed that there must be ap articular susceptibility in an individual that could trigger these kinds of diseases, but parameters have not yet been well clarified, except for CD, [5] for which HLA-DQg enes are of invaluable importance in the diagnosis given that virtually all CD patients (> 97 %) carry the coding variantsf or HLA-DQ2 and/or HLA-DQ8 molecules.
[6] However,a lthough carriage of the HLA-DQ2/DQ8 haplotype is an essential factor in the pathogenesis of CD, it has low predictive value. [5] Thisi si llustrated by the fact that whereas 30-40% of the general population carriest his genotype, the prevalence of CD is about 1% worldwide. [7] Genome-wide association studies (GWASs) have shownt hat there are also non-HLA genes involved in the disease. [8] Up to now,d iagnostict ools for diagnosis exist only for CD and dermatitis herpetiformis. In the case of CD, these strategies are genetic markers (HLA-DQ2/DQ8), specific serological antibodies (anti-transglutaminase antibodies), histopathological analysiso ft he duodenal-jejunal biopsy specimens,a nd the clinicalr esponse to the implementationo fagluten-free diet (GFD). [9] CD is the most common food intolerance in western society. [11] It is an autoimmune enteropathy that mayp resentn ot only with intestinal manifestations but also systemic ones, such as anemia, loss of weight, short stature, osteoporosis, and peripheraln europathy. [12] Other specific conditions associated with CD are, for example, Addison's disease, non-Hodgkin lymphoma,n eurologicald isorders, andt ype Id iabetes mellitus. [13] As CD cannot be cured pharmacologically, [14] the only effective Gluten-related disorders are ac omplex group of diseases that involvet he activation of the immune system triggered by the ingestion of gluten. Amongt hese, celiac disease, with ap revalence of 1%,isthe most investigated,but recently,anew pathology,n amed nonceliac gluten sensitivity,w as reported with a general prevalenceo f7 %. Finally,t here other less-prevalent gluten-related diseases such as wheat allergy,g luten ataxia, and dermatitis herpetiformis (with an overall prevalence of less than 0.1 %). As mentioned, the common molecular trigger is gluten, ac omplexm ixture of storagep roteins presenti n wheat, barley,a nd av ariety of oats that are not fully degraded by humans.T he most-studied protein relatedt od isease is gliadin, present in wheat, which possesses in its sequence many pathological fragments. Despite al ot of effort to treat these disorders, the only effective method is al ong-lifeg luten-free diet. This Review summarizes the actual knowledge of glutenrelated disorders from at ranslationalc hemistry pointo fv iew. We discuss what is currently known from the literature about the interaction of gluten with the gut and the critical host responses it evokes and, finally,c onnect them to our current and novel molecular understandingo ft he supramolecular organization of gliadin andt he 33-mer gliadin peptide fragment under physiological conditions. treatment for gluten-related disorders is al ife-long abolishment of gluten from the diet. As trict gluten-free diet (GFD) improves the clinical symptoms, diminishes the titers of the CD-specific antibodies, andfinally heals the intestinal mucosa and restores health.I nd aily life, adhering to aG FD appears to be difficult and has ah uge impact on the quality of life of the patient.
[15] The two main long-term complications of not following aG FD in CD are osteoporosis and malignancy.A lso, prolonged gluten consumption in nondiagnosedi ndividuals may contributet ot he refractory forms of CD, forw hich there is no response to aG FD and, therefore, intestinal inflammation is maintained. There are two forms of refractory CD:t ype I, which responds to immunomodulators, andt ype II, for which there is no effective treatment, and this type is associated with an increased incidence of Tcell lymphoma. [16] In thesed ays, there is ab road field of research dedicated to findingn ew alternatives that reduce the immunogenicity of gluten in cereals to prevent people from triggering an immune response.
[17] The most-advanced studies are devoted to prolyl endopeptidases degrading toxic gluten peptides (ALV003, AN-PEP) [18] For AN-PEP [19] and larazotide acetate (AT-1001, human zonulin inhibitor), [20] clinicalt rials have been conducted. However,t hey will not become an alternative to ag luten-free diet but rather as upplement to it, which will enablep atients to ease nutritional restrictions.A nother potentially promising approach is nutritional therapy.V arious dietaryc omponents including long-chain w-3f atty acids, plant flavonoids, and carotenoidsh aveb een demonstrated to modulate oxidative stress, gene expression, and productiono fi nflammatorym ediators. Therefore, their adoption could preserve intestinal barrieri ntegritya nd, hence, could play ap rotective role against toxicity of gliadin peptides. [21] The other gluten-related disorders are much less understoodf rom am olecular perspective.A ctually, in the case of nonceliac gluten sensitivity the diagnosis can only be made by exclusion of gluten from the diet (refer to more specialized Review articles [4, 9] ). Taking into account the increaseds pectrum of gluten-related disorders and the estimated high and increasing prevalence of these diseases, [4, 14] it is highly desirable to come to af ull understanding of these pathologies from am olecular point of view to provide better diagnosis and appropriate treatment.
What is Gluten?AGeneral Description
All aforementioned gluten-related disorders have ac ommon trigger,t hat is, the contact or consumption of gluten. The term "gluten", as describedi nt he dictionary,i s" the tough, viscid, nitrogenous substance remaining when the flour of wheat or other grain is washed to remove the starch and it gives to dough its tough elastic character". [22] From ac hemical point of view,g luten is composed mainly of proteins with ah igh content of the amino acids glutamine and proline in their sequence, generallyr eferred to as prolamins. In the seed, prolamins act as as torages ource of nitrogen for germination. [23] The major prolamin from wheat is gliadin, but homologous proteins are found in barley (hordeins), rye (secalins),a nd oat (avenins). The prolaminp roteins of these cereals undergo incomplete enzymaticd egradation during in vivo digestion, which produces peptides that result in toxicity in predisposed individuals. In wheat gluten, there are two main types of proteins:o ne is the alcohol-insoluble fraction,w hich is traditionally called glutenins, and the alcohol-soluble fraction called is gliadins. [24] 
The Structure of Gliadin Proteins
The most-studied protein related to gluten-consumption diseases is gliadin, the prolamin from wheat.
[25] It is composed of different isoforms that are classified as a (25-35kDa), b (30-35 kDa), g (35-40 kDa), and w (55-75 kDa) depending on their electrophoretic mobility. [26] These proteins share as imilar primary structure consisting of an N-terminal domain;ahydrophobic centrald omain that is rich in proline, glutamine, and phenylalanine;a nd an onrepeatingr egion includingc ysteine ( Figure 2) . The a-a nd b-gliadins have between 250 and 300 amino-acid residues with avery similarstructure and sequence, so they are usually grouped.A lso, a/b-a nd g-gliadins contain six and eight cysteine residues,r espectively,t hat are located in ac onserved position. The w-gliadin possesses3 50 amino acids and is globally more polar than the resto ft he isoforms. It does not contain the amino acid cysteine in its composition, and for that reason, it is not able to presentac ross-linking through disulfide bridges. [27] Similar to other gliadins, w-gliadin is also characterized by high contentso fp roline and glutamine, which are located in ar epetitive and characteristic sequenceP QQPFPQQ.
[28] All gliadins possess few positively charged amino acids. Although this group of proteins has been studied extensively, elucidation of their secondary and tertiary structuresi ss carce. Whereas under normale nvironmental conditions crystallization of the proteins fails, in am icrogravimetric environment it is possible to elucidate their structure. [29] The main reason for the lack of structural information is the low solubility of gliadin in water,i ts high molecular weight, and its high proline content.
[25c] These intrinsic characteristics make it difficult to obtain structural information Figure 1 . Pathogenesis of gluten-related disorders. The percentages correspond to the prevalence of each disease in the generalp opulation (adaptedf rom Sapone et al. [10] and Fasano et al. [4] ).
ChemistryOpen 2018, 7,217 -232
www.chemistryopen.org 2018 The Authors. Publishedb yWiley-VCH Verlag GmbH &Co. KGaA, Weinheim through high-resolutiont echniques such as nuclearm agnetic resonance or X-ray diffraction. That is why structural information for this protein has been obtained mainly from spectroscopic techniques. [30] Gliadin can be solubilized in water by using mixtures of salts and alcohols. Using Ramans pectroscopy,B lanch et al. [31] have shown that a-gliadins possess ah igh a-structure content,a nd to al esser extent, b sheet and polyproline II (PPII) structures at pH 3.5. In the case of w-gliadins, a well-defined PPII structure hasb een determined with some b turns at pH 2.6. Moreover,T atham and Shewry have shown by circulard ichroism that an ethanol solution (70 %, v/v)o fa-, b-, and g-gliadins presentsw ith 36-37 % a helix, 11-12 % b sheet, and 52-53 %r andoms tructure and b turns.T hey also describe that a-, b-, and g-gliadins are stabilized by hydrogen bonds and disulfur bridges, whereas w-gliadins are stabilized by hydrophobic interactions. [32] 5. The Self-Assembly Properties of Gliadin:
AS upramolecular View
Previous studies have pointed out that gliadinc an self-assemble under different conditions in aqueous media. By desolvation, gliadin generates spherical aggregates with diameters in the range of 100 to 500 nm. This methodc onsists of treating a protein with ap recipitants olvent and has been employed to obtain nanoparticleso fg liadin as ac olloidal system for drug delivery.
[34] Additionally,g liadin self-organizes in aqueous media to form metastable supramolecular structures. Kasarda et al. have demonstrated that a-gliadin reversiblya ggregates into fibrils at pH 5.0 in acetic acid and lowi onic strength, and this process can be modulated by loweringt he pH. [35] Moreover,S ato et al. have shown that as olution of gliadin in distilled water below 10 wt %w ith high ionic strength is composed mainly of ellipsoid monomers that are 11.3 nm in length and 2.5 nm in width, with smalla mounts of dimers and oligomers. Above 15 wt %, gliadins form gel-like hydrateds olids, and at higher concentrations,l arger aggregates are present. [36] More recently,i th as been reported that if am ixture of commercial gliadins is dissolved and homogenized in water at pH 3.0 under low ionic strength, a-a nd b-gliadins self-organize ( Figure 3 ). The self-assembly process is spontaneous, and nanospherical structures are stabilized in the transparent water solution.I ft he pH is changed to 7.0, phase separation is observed, whereas the a-gliadins remaini ns olution as nanoparticle aggregates. Although no differences are detected in the secondary structure at either pH value, differential exposition of tyrosine and tryptophan is observed, whichc an be caused by at ertiary structure change. To evaluates tructuralc hanges, such as the exposure of hydrophobic sites, Nile Red (NR) fluorescence can be employed. By using this technique, this fluorophore increases the fluorescenceo fa-gliadin and the maximum emission is blueshifted at pH 3( relative to that of pure a-gliadin), but not at pH 7.0. This behavior is indicative of NR bindingt og liadin and suggests that hydrophobic sites are accessible at pH 3.0. These resultsf urther indicatet hat at pH 3.0 the system is self-organized as micellar nanostructures,w hereas at pH 7.0t he structures have al ower surface charge (from + 13 mV at pH 3.0 to + 4mVatp H7.0) and colloidal nano-and microparticles are detected. [37] The formationo ft hese nanostructures in the digestive system may block the degradations ites of the digestive en- Figure 2 . Sequence alignment of representative sequences of a-( Q9FUW7), a/b-( P08453), g-(Q9M4L6) and w-gliadins (P18573) by using ESPript3.0. [33] The conserved residues are in whitew ith ar ed background. Residues in red are similar within agroup, and residuesf ramed in bluea re similar across groups. Figure 3 . Supramolecular organization of gliadin in aqueousm edium reported by Herrera et al. [37] Although bothsolutions are cleara nd transparent, gliadin molecules are not randomly dispersed in water;instead,t hey self-assemble to form micellar oligomerso rn anoparticlesd epending on the pH value.
ChemistryOpen 2018, 7,217 -232 www.chemistryopen.org 2018 The Authors. Publishedb yWiley-VCH Verlag GmbH &Co. KGaA, Weinheim zymes. By simulation, the a-2 gliadin protein is anticipated to be cleaved by pepsin in 48 positions and by chymotrypsin in 35 locations, but in reality,t his does not happen. In that case, the supramolecular behavior of gliadin under physiological conditions at pH 3.0 and 7.0 offers an essential clue to the understanding of why pepsin or chymotrypsin in vivo does not fully degrade this protein. Of course, once in the small intestine the high amount of proline plays ac rucial role in endopeptidase activity,b ut the high contento fp roline by itself does not explain the proteolytic resistance observed.
The Interaction of a-Gliadin and Its Proteolytic-Resistant Peptides with the Intestinal Mucosa
Amonggliadins, the a-gliadin isoform and itsdigest (proteolytic-resistant fraction after pepsin and trypsin digestion) are frequently used to study the gliadin-mediated effects on primary cultures andc ell lines. [38] The rationaleb ehind this choice is that the gliadin digest most closely mimics the in vivos ituation. Due to gliadin's incomplete degradation,avast array of mostly unknown small and large peptides comes into contact with the gut epithelium and after transcellular and/or paracellular translocation with the lamina propria,t hey can be recognized by the mucosal immunesystem.
The Gut-Associated Lymphoid Tissue
The mucosal immune system has the relevant task to distinguish which of the many luminal antigenst hat it encounters are benign to the host, for instance, food proteins and commensal flora, and which of them form ad anger to the host, for instance, invading pathogens. Under normalc onditions, a milieu of immune tolerance reigns at the mucosal site, but the mucosali mmune system must possessareadiness to mount an adequate proinflammatory immune response to dangers ignals to protect the host. Different cell types take part in these elaborate dynamics. [39] Intestinal epithelial cells (Figure 4a )a re the first level of control, as they "sense" the nature of the luminal environment (Figure4b) ands end crucial information to underlying immunecells, for example, by the production of cytokines and expression of membrane receptors (Figure 4c-e) . The gut-associated lymphoid tissue from the smalli ntestine consists of effector sites, that is, scattered lymphocytes in the lamina propria (Figure 4f )a nd epithelium and organized tissues such as Peyer's patches and mesenteric lymph nodes (Figure 4g,h ). In particular,t he mesenteric lymph nodes are crucial for the induction of tolerance and immunity.G enerally,t he antigen is taken up by dendritic cells andispresented in the context of HLA class II to CD4 + Tcells. [40] Possible places at which antigen uptake can occur are Peyer's patches (Figure 4g )a nd, if the antigen has gone throught he epithelial monolayer,t he villous lamina propria (Figure 4f ). The antigen-loaded dendritic cells within the Peyer's patches can present to CD4 + Tcells in loco or can migrate from the Peyer's patches via afferent lymphaticst ot he mesenteric lymph nodes and present there to CD4 + Tcells. Likewise, villous lamina propria dendritic cells can reach the mesenteric lymph node via afferent lymph vessels, and there they present the antigen to CD4 + Tcells (Figure 4g-i) . Wherevert he site of antigen uptake may be, all antigen-primed lymphocytes obtain the intestinal homing molecule, a4b7, and leave the mesenteric lymph node via efferent lymph vessels and re-enter the intestinal mucosa at which they take their particularp lace. For example, Bcell blasts mature into IgA-producing plasma cells and remaini nt he lamina propria (Figure 4k ), CD4 + Tcells are distributed over the villus laminap ropria (Figure 4j ), whereas most CD8 + Tcells migrate to the epithelium. The Tcells can provide help as effector cells to Bcell plasmablasts to produce IgA, and they can be antigen-specific memory CD4
+ and CD8 + Tcellso rr egulatory Tcells. CD8
+ Tcells also can exert strong cytotoxic activity,usually to antigens that are present in the context of HLA class I molecules.
[40b]
Antigen-primed CD4
+ Tcells are involved in local immune regulation and produce large amounts of interferon (IFN)-g,i nterleukin (IL)-4, and IL-10.
[41] The coexistence of these different cytokines is af eature of normalh omeostasis, and disturbances in their secretion reflect pathogenesis of gastrointestinal disorders, such as the high mucosal titers of IFN-g in the active phase of CD. [42] The production of IL-10 is essential in the maintenance of tolerance (Figure4e, i, j), whereas in immunity it is crucial in the regulation of inflammation.
[41b] In addition to the environmental factors derived from the intestinal lumen, such as food proteins or bacterial products, genetically determined (host) factors may impact the immunological outcome. As professional antigen-presenting cells, the dendritic cells integrate these genetica nd environmental factorsand shape the Tl ymphocytes, to which they present the antigen,t om aintain intestinal homeostasis or to induce immunity.O ther features of intestinal tolerance are the abundant production of the cytokines TGF-b and IL-10 by tissue macrophages, mesenchymal cells, and epithelial cells and, furthermore, the production of the enzymec yclo-oxygenase 2( COX-2) by epithelial cells (Figure 4c ). COX-2 is an essential mediator in the synthesis of prostaglandin-2 (PGE2)f rom arachidonic acid, and it fulfills ac rucial role in immune tolerance. PGE2 increases IL-10 production,d ecreases proinflammatory mediators such as HLA class II, IL-12, tumorn ecrosis factor (TNF)-a,a nd primes dendritic cells to shape Tcells to tolerogenic and regulatory Tcells (Figure 4e,i) . Inhibition of COX-2 in am urine model results in features characteristic of celiac disease possibly due to T-lymphocyte stimulation in an environment deprived of COX-2-dependent arachidonic acid metabolites. [43] In case pathogens are encountered, local inflammation is induced by Toll-like receptor (TLR)-mediated productiono fi nflammatory mediators, such as IL-1, IL-6, and IL-8 by macrophages, mesenchymal cells, ande pithelial cells ( Figure 5a ). This inflammatorye nvironments hapes the dendritic cells (DCs). As ar esult, the DCs undergo complete maturation after havingt aken up the antigen in the Peyer's patches or lamina propria (Figure 5b )a nd start to produce the proinflammatory cytokineI L-12. Under these circumstances, antigen presentation to naïve CD4
+ Tcells leads to their differentiation into gut-homing Th1 cells, which produce IFN-g and causef urther Figure 5c ). Likewise, plasmablasts home to the intestinalm ucosa and mature into IgA-secreting plasma cells (Figure 5d ). These events lead to local immunity and IgA production.
The (Patho-)Physiological and Immunogenic Properties of the Gliadin Digest
Gliadin digest induces physiological changes and immunological responses, many of which are observed in both health and disease, albeit the measure of these effectso fg liadin is much higher and prolonged in disease. In this scenario, specifica nd characteristic for the activep hase of celiac disease are the presenceo fg liadin-restricted Th1/Th17T -cell-mediated immune responses (Figure5c, e) , [42, 44] an increase in intraepithelial lymphocytes (Figure 5f ), and villus blunting (Figure 5g ).
In the gut lumen, the gliadin digest first interacts with the intestinal epithelium. It is still am atter of debate how gliadin and its digestive fragments pass the enterocyte monolayer,but availablei nformations uggests the involvement of both transcellular ( Figure 5g,h )a nd paracellular pathways (Figure 5i) . Some evidencef or endocytosis of gliadin and its digest is shown by the finding that gliadinf ragments induce remodulation of the actin cytoskeleton, which interferes with the brushborder membrane traffickingo fv esicles. [45] Another school of thought includes the possibility of paracellulart ransport over the intestinal epithelium.
[46] In this respect, it has been shown that the gliadin digestb inds to the apically expressed chemokine receptor (CXCR3). [47] Gliadin's interaction with CXCR3 induces the secretion of zonulin, ap hysiological modulator molecule of intestinal permeability,w hich in turn binds, through transactivation of the epithelial growth factor receptor (EGFR), to protease-activatedr eceptor 2( PAR2). [48] These interactions lead to reorganization of the cytoskeleton, which results in disassembly of the tight junctions, interepithelial protein complexes that regulate permeability.
[44] Barone et al. [49] report an epithelialg rowth factor (EGF)-like effect of gliadin, including EGFR activation, rearrangement of the actin cytoskeleton, and changes in cell cycle and cell proliferation (Figure 5j ). Using normalm ice and MyD88-deficient mice, Thomas et al. [50] have shown that the effects of gliadin digesto ni ntestinal permeability andz onulin releaser equires MyD88 recruitment. Althought he involvement of MyD88 commonly indicates signaling by TLRs, this study shows that the two most plausible-if any-candidates, TLR2 and TLR4, seem not to be implicatedi n this response. Although it cannot be excluded that other TLRs might be involved in gliadin-induced intestinal permeability, the CXCR3 chemokine receptor has been found to co-localize with MyD88 and appearst op ossess aT oll/Interleukin receptor (TIR)-liked omain, which strongly suggesting its (mere) involvement in gliadin-induced, MyD88-mediated signaling. [47] In cultured duodenal biopsy specimens from healthy individuals and celiac patients,D rago et al. [51] have confirmed that gliadin and its digested fraction inducet he release of zonulin and increase intestinal permeability and, furthermore, report disease-specific qualitative and quantitative differences. Thus, whereas the release of zonulin and an increase in permeability are small and short-lived events under healthy conditions, both the release of zonulin and the accompanying breach of barrierf unction are massive and difficult to restorei nc eliac tissues. Notably, during the active phase of celiac disease, in addition to increasedi ntestinal permeability zonulin titers are elevated [52] and mucosal expression of CXCR3 is increased (Figure 5i,k) . [47, 53] Figure 5f urtherd epicts inflammatory features that have been described explicitly for CD, the gluten-induced autoimmune enteropathy that is characterized by aberrant Th1/Th17 T-cell-mediated immunity and auto-antibody production leading to severe intestinal damage (Figure 5e-m) . See text for detailed discussion of these features.
All markersr eturn to baseline expressionl evels after implementation of ag luten-free diet once the disease goes into remission. Gliadin's interaction with intestinal epithelium produ- ces stressfule ffects such as an oxidative imbalance, [38] the productiono fI L-15 and IFN-g, [54] and apoptosis if the cells are exposed to gliadin for 48 h. [55] Furthermore, the gliadin fragments can induce both an upregulation of epithelial expression of HLA-E and MICA (major histocompatibility complexc lass I chain-related gene A) molecules, which are ligands for their respectiver eceptors, CD94 andN KG2D,a nd selective expansion of subsets of intraepithelial CD8
+ cytotoxic Tl ymphocytes that express CD94 and NKG2D. [56] These pathways are thought to be mechanisms that regulate cytotoxic T-lymphocyte activity in injured cells, thereby minimizing potential damaget oa djacent intact cells. Usually,cytotoxic Tlymphocytes need co-stimulation with T-cell receptor (TCR)s ignaling, but recent studies convincingly show that IL-15 can inducec hanges in the NKG2D signaling pathway that allowsf or aT CR-independent conversion of CD8 + cytotoxic Tl ymphocytes into natural killerlike cells. Most of these eventsa re inhibited by neutralizing antibodies to IL-15, which thusc onfirms the key role of this cytokine as am ediator of intestinal mucosad amage. [57] Although the gliadin digest can induce epithelial IL-15 production under normalc onditions, [56, 58] IL-15 titers are much highera nd intraepithelial lymphocyte numbers are significantly increased in active celiac disease relative to healthyi ndividuals, which suggests ar ole for aberrant activation of the IL-15/NKG2Ds ignaling pathway in the massive tissue damage observedi na ctive celiac disease (Figure 5g) . [59] To understand furthert he effects of gliadin's digest on innate immune cells, peripheral blood mononuclearc ells and primary cells and cell lines from phagocytic lineageh ave been used in stimulation assays.I np eripheral bloodm ononuclear cells from healthy individuals and CD patients,t he gliadin digest induces the productiono fv arious cytokines, including TNF-a,I L-10, and IL-8. The latter cytokine appearst ob ep roduced in aC XCR3-mediated fashion only in CD patients.I ts cellular sourcesa re monocytes and plasmacytoid dendritic cells. [60] In normalm urine peritoneal macrophages, gliadin stimulates the production of TNF-a,R ANTES, IL-10, and IL-8 and as ignificant rise in nitric oxide (NO), another mediator of inflammation. These effects are dependent of prior primingo ft he cells with IFN-g. [61] Jelínkovµ et al. [62] report similar effects for the human monocyte cell lines, THP1 andU -937, with gliadin-induced production of IL-8 and TNF-a through the activation of the NFkBs ignaling pathway,a nd as ynergistic effect of IFN-g has also been shown in human cells. Thomas et al. [50] show in an ormalm urinemodel that the gliadin digest, in addition to MyD88-dependent release of zonulin and increasedi ntestinal permeability,a lso induces the production of proinflammatory cytokines, among which are TNF-a,I L-12, IFNb,a nd CXCL10, by macrophages. As signaling through TLRs recruits the adaptor molecule MyD88 and leads to NFkBa ctivation, the studya ssesses ar ole for TLR2 and TLR4 in gliadin-induced immune responses but does not find evidencef or their involvement. In contrast, Palovµ-Jelínkovµ et al. [63] have found that TLR4 is involved in gliadin-digest-induced NF-kBactivation and IL-1b production by human monocytes. As the effects are not observed after stimulationw ith synthetic gliadin peptides, the authors do not exclude that another component within the digest, for instance, the amylase tryptase inhibitor for which aT LR4-mediated effect was previously described by Junker et al., [64] could be responsible for the observede ffects. Another effect of gliadin is its neutrophil chemoattractant properties. [65] Upon applyingg liadin digest in the intestinal lumen of C57BL/6 Lys-eGFP mice, CD11b + Ly6G + cells (a subset consisting of murinem acrophages and neutrophils)r apidly migrate from the vessels into the lamina propria. With in vitro chemotaxis assays,m igrationo fi solated murine and human neutrophilst ot he gliadin digest has been shown.N otably,t he gliadin digest and the classical neutrophil chemoattractant, f-Met-Leu-Phe, both induce similarn eutrophil migration. Specific inhibition of the f-Met-Leu-Phe receptor,t he formyl peptide receptor 1( FPR1), not only blocks neutrophil migration towards f-Met-Leu-Phe but also towards gliadin,w hichi ndicates that gliadin also binds to FPR1. [65] The adaptive immune response specific for celiac disease consists of aT h1-mediated mucosal immune response of gliadin-specific CD4
+ Tcells with ap articular cytokine pattern (IL-10
[ 57] Recently,r eports have described the presence of Th17 cytokines in active CD, in particular IL-17A, [44] which suggestst he involvement of aT h17-mediated immune response in CD (Figure 5e) . Important in the regulation of the Th17-mediated immune response are the CD4 + CD25 ++ FoxP3 (forkhead box protein 3)
+ regulatory Tcells. [66] Although regulatory Tcells are increased in number in active CD, [67] their suppressivef unction seemsi mpaired (Figure 5i ).
[68] Granzotto et al. [68b] show that regulatory Tcells from CD patientsa re impaired in their ability to suppresst he proliferationo fC D4 + CD25 À responder cells after CD3/CD28 co-stimulation in comparison to regulatory Tcells from healthyi ndividuals (Figure 5c ). In their study, Serenae tal. [68a] demonstrate overexpression of the alternatively spliced isoform of FoxP3 in CD mucosa. Thiss plice variant cannotproperly downregulate the expressionofR ORgt,atranscriptionf actor that is essential in Th17 differentiation, possibly favoring skew towards aTh17immune response (Figure 5e ). 
Identification of Gliadin Peptides and Their Pathological Role
Gliadin peptides can be classified as "toxic" or "immunogenic" depending on their ability to induce intestinal damage in vivo and/or in vitro or to activate Tcells, respectively. [69] Specific synthetic gliadin fragments recapitulate many of the abovementioned effects of the full gliadin digest. A1 3-mer peptide, derived from a9-gliadin (aa [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] , has been reported to be toxic.
[70] Another fragment 33 amino acids long is recognized as the most proteolytic-resistant and immunogenic peptide and is nameda33-mer gliadin peptide( aa 57-89 from a2-gliadin). [25a] More recently,T uckova et al. have identified 12-mer and 14-mer peptides. [61] Lammers et al. report aC D-related 17-mer peptide (aa 270-286), [60] two intestinal-permeating 20-mer peptides (aa 120-140, aa1 60-180), and an umber of 20-mer neutrophil chemoattractant peptides. [65] 7.1. The Toxic 13-mer Gliadin Peptide(aa 31-43)
The 31-43 peptide sequence has been detected mainly in a-9 gliadin (Figure 7) . It was first obtained by in vitro cyanogen bromide cleavage, and this sequence has been tested as as ynthetic peptidei nj ejunalm ucosa of untreated patients and has been shown to induce histological damage.
[71] From an immunological perspective, this peptide induces several pleiotropic effects without binding to HLA-DQ2/DQ8 and without stimulating CD4 + Tcells. These effects include rapid production of inflammatory mediators, such as IL-15 and COX-2;u pregulation of CD25 on non-T cells (CD3-negative cells);a nd CD83 expression on resident dendritic cells in the laminap ropria. [70b, 71] Furthermore, the peptide increases the intraepithelial migration of CD8 + Tcells and CD94 + cells and increases enterocyte apoptosis. The results are dependento nI L-15, as the addition of neutralizing antibodies to IL-15 abrogates the effects (Figure 5g) . To explore the in vivo effect of this peptide, Araya et al. have applied the peptide intraluminal in the intestine of normalm iced uring surgery and have studied the responses in these mice. The resultss how that the peptide causes histological changes similart ot hose observed on CD, such as increased intraepithelial lymphocytes and reduced villus-crypt ratio. Furthermore, the peptide induces an increase in epithelial cell death and increases titers of inflammatory mediators, in particular of type Iinterferon. These effectsare dependent on the recruitmento fM yD88, but ar ole for TLR4 can be ruled out.I nterestingly,c o-administrationo fp oly I:C, the ligand for TLR3, enhances the immuner esponse. As TLR3 is known for its specificity to recognize viral single-stranded RNA, the authors conclude that the gliadin peptidep 31-43 can activate the innate immune pathways in vivo and suggest ap otential interaction may exist between dietary gluten and viral infections. [72] One crucial intracellular pathway implicated in the pathogenicity of the 13-mer peptide is EGFR activation. Upon exposure to the 13-mer peptide, both the Caco-2 cell line and culture biopsys pecimensfrom CD patientsshowsigns of actin remodeling and cell proliferation reminiscent of the effects induced by EGF.A lthough not al igand for EGFR, the 13-mer peptide prolongs activation of EGFR by interfering with EGFR endocytosis.
[73] In another study,B arone et al show that in as earch for sequence similarity,t he 13-mer peptider esembles hepatocyte growth factor regulated tyrosine kinase substrate (Hrs), which is ac rucial regulator protein of endocytic maturation.T he observed accumulationo ft he 13-mer in the early endosomes might then occur because the peptide would interfere with Hrs and its properf unctioning. As ac onsequence, the 13-mer delaysm aturation of early endosomes into late endosomes, the compartment in which degradation of peptides takes place,a nd additionally,i td elays EGFR degradation.
[73a] The perpetuation of EGFR activation may be of importance in the development of epithelial blunting, as observed in active CD (Figure 5j) . Luciani et al. show the accumulationo ft he peptidei n LAMP-containing lysosomes. The continued presence of the peptidei nt he cell causes cellular stress, as measured by an increase in the levels of radicalo xygen species, elevated titers, and activationo ft issue transglutaminase 2a nd downregulation of peroxisome proliferator activatorr eceptor (PPAR)-g, which activates the innate immune response. [74] Another criticalt opict oe valuate is how the 31-43-mer can travel through the gut mucosa. Vilasie tal. have shown with a simple micellar model that this peptide can possibly interact with membranes. [75] Ar ecent study making use of chemical cross-linking to stabilize the peptide on proteins expressed on the cell surface andp ull-down of the peptide-protein complexesw ith antibodies raised against peptide3 1-43 did not find specific complexes between cellular proteins and the 13-mer peptide. Also, in competitive binding experiments the peptide could not displace bound peptide, which suggests nonspecific binding. On the basis of this result, the authors hypothesize that no receptor might be involved in the trafficking of the 13-mer peptide. [76] 7.2. The Immunodominant 33-merG liadin Peptide (aa 56-87)
The 33-mer peptide (see Figure 7) was obtained by Shan et al. [25a] after the enzymatic degradation of a-2 gliadin by gas- tric, pancreatic,a nd brush border peptidases. Recently,t he quantification of the 33-mer by liquid chromatography tandem mass spectrometry in different wheat speciesa nd cultivars has been performed. This report shows that after proteolysis, the 33-mer remains in the range of 91 to 603 mgg À1 in wheat flour, which justifies the importance of this fragment in the human diet. [77] This highly proteolytic-resistant peptideh arborss ix epitopes that are in part overlapping. By an unknownm echanism, it reaches the lamina propria,a tw hich dendritic cellsp rocess and present it in the contextofH LA-DQ2/8 to CD4
+ Tlymphocytes. [25a] In general, proteins cross the epithelium by the transcellular pathway followed by lysosomal degradation.A sf or the other gliadin peptides,t here is an ongoing debate on the mechanism of epithelial translocation. Schumann et al. [78] have studied 33-mer peptidet ranscytosis in Caco-2 cells and duodenal biopsy specimens from healthyi ndividuals and activeC D patients and have found evidencef or transcellulart ransport of the 33-mer peptide to the lamina propria througha ne ndocytic pathway involving Rab-5. Addition of IFN-g,t he hallmark cytokine in active celiac disease, enhances translocation of the peptidei nC aco-2c ells. Compared to duodenal tissuesf rom healthyi ndividuals and CD patients in remission, tissues from active CD patientsr eveal significantly highere pithelial uptake of the peptides eemingly localized in endocytotic vesicles. The data presented by MØnard et al. [79] suggest at ranscellular pathway for the 33-mer peptide. Their immunofluorescent images show co-localization of the peptidew ith early endosome antigen 1, which indicates that the peptidee nters the early endosomes.H owever,n oc o-localization is found with lysosomal-associated protein 2, which suggests that the peptide does not enter the late endosomes or lysosomes, the cellular compartment in which peptided egradation is thought to occur.T hese authors hypothesize that this is in line with their other study, [80] in which they demonstrate that the 33-mer peptide is transported to the lamina propria while escaping the lysosomal compartment by binding to lumenals ecretory immunoglobulinA (sIgA);t hus, lysosomal degradation was impaired. The gliadin-sIgA complex is recognized by the apically expressed transferrin receptor,C D71, and is "retrotranscytosed" to the lamina propria (Figure 5h ). This mechanism would only occur in active CD, for which, in contrast to the healthy condition in which CD71 is solely expressed at the basolateral site of the cells, the receptor is aberrantly expresseda tt he apical side of the enterocyte. Finally,B ethune et al. [81] describet wo possible mechanismsf or epithelial translocation of the 33-mer peptide by using aT 84 cell-culture model.I nr esponse to conditioned mediumf rom gliadin-treated Tcell cultures from CD patients, epithelial cell permeability is increased and apically applied 33-mer peptidesm ake use of the paracellular pathway to translocate. This process occurs mainly in the presence of high concentrations of IFN-g,a nd the addition of neutralizing antibodies to IFN-g or anti-IFN-g-receptor blocking antibodies inhibits paracellular transport. In the absence of gliadin-conditioned mediumo rI FN-g,t ranscellular transport of the 33-mer seems to take place without the involvement of ar eceptor. These authors conclude that under healthy conditions, gliadin peptides use the transcellular pathway in ar eceptor-independent way though fluid-phase endocytosis, whereas under inflammatory conditions an IFN-g-induced increase in the intestinal permeability results in increased paracellular translocation of gliadin.
In celiac patients, ac haracteristic and well-known T-cell response (adaptive immune response) is observedi ft he peptide enters the gut mucosa. In the lamina propria,t he 33-mer peptide is ah igh-affinity substrate for tissue transglutaminase 2, an enzyme that deamidates three glutamines to glutamic acid (Figure 5m ). This deamidated peptidei sm uch more immunogenic and induces as tronger adaptive immuner esponse. Additionally, the 33-mer peptide contributes to b-cell hyperactivity observed before the onset of type 1d iabetes, at least in murinem odels. [82] Some researchers have considered that gliadin and its 33-mer fragment are handled by the host as if it were apathogen such as abacterium or avirus. [83] However,althought here is much evidence pointing in this directiont here is no sound explanation for the observed similarities.
Other Identified Gliadin Peptides
It is important to notet hat frequently the exact peptide compositiono fagliadin digest is unknown. For this reason, Tuckova et al. have identified different peptides from the peptic gliadin digest by reverse-phase (RP)-HPLC-MS. These authors report that a1 4-mer fragment, VSFQQPQQQYPSSQ (named the T peptide), and especially its shorter 12-mer form, FQQPQQQYPSSQ (namedt he B peptide), elicit the highest TNF-a,I L-10, andR ANTESs ecretions and an increasei nI FN-gprimedn itric oxide production in mousem acrophages. [61] Likewise, thesep eptides induce IL-8 and TNF-a through activation of the NFkBp athway in the human monocytic cell line, THP-1. [62] Another approachd escribed by Lammers et al. involves the generation of a a-gliadin synthetic peptide library consisting of 25 20-mer peptides each overlapping in 10 amino acids. This library has been used to identify the fragments responsible fort he observed gliadin-digest-induced effects (Figure 7) . [47] Atotal of 16 novel gliadin peptides have been described to be involved in three differentr esponses, for example, intestinal permeating effects, [47] immunogenic effects, and neutrophil migratory effects. [65] Using the synthetic a-gliadin peptidel ibrary,t wo peptides, QQQQQQQQQQQQILQQILQQ (aa 120-140) and QVLQQSTYQLLQELCCQHLW( aa 160-180), have been identified as the specific gliadin fragments that bind to epithelial CXCR3 (Figure 5i) . Furthermore, unlike nonbinding peptides, theset wo CXCR3-binding peptidef ragments also induce tight junction disassembly.T he second finding is related to gliadin-digest-induced immune stimulation of peripheral blood mononuclear cell cultures and shows that the cellular response to gliadin is differentially regulated in CD than in health with the involvement of the CXCR3 chemokine receptor. In this study,t he cell cultures from both healthy individuals and celiac disease patients respond to gliadin digest by producing substantial titerso fa na rray of proinflammatory mediators, including interleukin-8. [60] Solely in the wells that contain cells from celiac patients,b ut not those containing cells from healthyi ndividuals, ap reincubation step with an antibodyt hat blocks CXCR3 before stimulation with the gliadin digestr esults in complete inhibition of IL-8 production. With the use of the abovementioned synthetic a-gliadin peptidel ibrary,athird peptide, PPYCTIVPFGIFGTNYR (aa 270-286), shows ar esult similar to that obtained with the gliadin digest regarding the CXCR3-mediated production of IL-8 by cells from the phagocytic lineage from CD patients. Finally,t his approach has allowed the researchers to individuate another 13 peptides that induce FPR1-mediated, moderate-to-strong neutrophil migration.
Altogether,t hese findings reveal exciting information on agliadin and illustrate the molecular complexityo ft he protein and its interaction with the host.
The Supramolecular Behavior of 33-mer Gliadin Peptide:ANew Hypothesis
There is evidence that the 33-mer peptidei st ransported within the body because it is detected in urine and feces. [84] It seems that the 33-mer gliadin peptide can escape all the proteolyticp athways involved in digestion;i tc rosses the gut epithelium and reachest he lamina propria at which it inducesa n immune responsei ns usceptible individuals. Up to now,t he immunogenic effect of the 33-mer peptidei nC Dh as only been explained by T-cell recognition.H owever, there is no explanation to put forward all the other exceptional properties of this gliadin fragment.
The immunogenicity of ap rotein or peptide depends not only on its primary sequence but also on the secondary and tertiarys tructures. Because of this, the structuralf eatures of the immunodominant 33-mer peptidea re essential to understand gluten-related pathologies. Initially, it was reported that the 33-mer peptide adopts aP PII (polyproline II) structure. [25a, 85] Then, am ore detailed circulard ichroism study,p erformed by Herrera et al.,h as shown that the 33-mer peptide suffers a conformational transition depending on the concentration under physiologicalc onditions. [86] At low temperature (À10 8C), at ac oncentration below 197 mm,t he peptidei si narandom coil structure, whereas at ac oncentration exceeding1 97 mm, the peptidei si na ne quilibrium between the random coil and am ore extended structure compatible with aP PII structure. The PPII structure is, in general, in equilibrium with other conformations,s uch as random and b structures due to the proximity of the respective dihedrala ngle. In at emperature-dependence experiment from À10 to 37 8C, it is possible to determinet hat at ac oncentration of 197 mm an equilibrium between the random coila nd the PPII structure exists, whereas at ac oncentrationo f6 13 mm as econd conformational equilibrium exists between the PPII and b structures. Under these experimental conditions, the 33-mer oligomerizes in ac oncentration-dependent manner.E lectron microscopy observations show that the 33-mer can oligomerize to form nanospheres, fibrils, and fibers that coexist together at 613 mm.M olecular dynamics simulation and partial charge distribution calculations have revealed that the 33-mer peptidei sanonionic amphiphile with the capability to form, at least, as table dimer. [86] Insight into the oligomerization process depending on concentration has been obtained by using dynamic light scattering (DLS) and atomic force microscopy (AFM). DLS experiments revealt hat at concentrations rangingf rom 125 to 610 mm,t he 33-mer gliadin peptide forms oligomers of different sizes. Three oligomeric populations have been identified:apopulation of oligomers with as ize smaller than 100 nm, as econd population of oligomers with sizes between 100 and 1000 nm, and at hirdp opulation of oligomers with sizes greater than 1000 nm. [87] These resultss trongly suggest that in aqueous solution the 33-mer peptide behaves as ad ynamic polydisperse system with nanometer-to-micrometer-sized particles, and at low concentrationst he smaller particles associate to generate bigger ones. However,a th igh concentrations, the biggerp articles seemingly act as new sites for nucleation,w hichl imits the interaction between the small ones.AFM observations visualize the differento ligomers in ah ydrated state without chemical manipulation. Deposition of an aliquot of a6mm solution onto am ica surfacer evels that the 33-merp eptidef ormsi solated spherical nanostructures and clusters. In the range of 60 and 250 mm,s pherical oligomers are associated with linear patterns forming annular structures (Figure 8 ).
Some planar structures show as heet-like morphology.A t the highest concentration of 610 mm,t here are mainly filaments and plaques surrounded by spherical nanostructures. At all the concentrationst ested, the 33-mer oligomers follow a diffusion-limited assembly (DLA) mechanism. The structural changes that take place during self-organization on as urface have been followed by using attenuated total reflectance Fourier-transform infrared (ATR-FTIR) spectroscopy.H ere, taking advantage of the fact that the absorption coefficient of the b structure is higher in IR spectroscopy than in circular dichroism, the nature of the b structure has been elucidated. Initially, the same concentration-dependent conformationale quilibrium that was previously detected in solution was confirmed.T he ATR-FTIR spectrum of the 33-mer aggregatesi nt he amide I (representative of protein secondary structure) region reveals two main bands. The intensity of the band at around ñ = 1630 cm À1 increases as af unction of concentration relative to intensity of the band at around ñ = 1660 cm À1 ,w hich suggests that the 33-mer peptideg oes from as omewhat unordered state to am ore folded state, enriched in b structures. Interestingly,i ft he peptideconcentration increases, larger structures is detected by microscopy techniques. Moreover,t he absence of ab and at around ñ = 1695 cm À1 ,c haracteristic of an antiparallel b-sheet structure, strongly suggests ap arallel b-sheet structure. [88] The PPII secondary structure is involved in protein-protein interactions, such as in motifs relatedt oS H2 domains, [89] and in proteins that form aggregates, such as the dental enamel protein amelogenin. [90] On the other hand, the conformationalt ransition towards ap arallel b structure is the hallmark signature of amyloid or conformationald iseases.T hese diseases involven ot only misfolding of endogenousp roteins, as seen in Alzheimer's disease, [91] but also exogenous proteins, as in the case of prion diseases. [92] In conformationald iseases, oligomers and fibril structures are detecteda nd associated with innate anda daptive immune activation. The observed conformational changes and oligomerization behavior of the 33-mer gliadin peptidec ould be the up-to-now unknownm olecular trigger that modulates immunea ctivation in glutenconsumption disorders. At the molecular level, the forcesi nvolved in the self-assembly process of the 33-mer are correlated with the primary structure of the 33-mer.T he 33-mer peptide contains 65 %p roline and glutamine, which suggests that hydrophobicity could be ad riving force for self-assembly. Moreover,i ti sk nown that glutaminer esidues can interact through complementary hydrogen bonding, in addition to the aforementioned hydrophobic effect.
[93] Glutamine (Q) can link b strandst ogether into b sheets by an etwork of hydrogen bonds between the amide groups of the chain and the polar side chains. [94] The importance of the Ql ateral chain in the formation of protofilaments has been highlighted in different amylogenicd iseases, including Huntington'sd isease. [95] Furthermore, supramolecular organizationo ft he 33-mer peptide in monomers, oligomers (with different morphologies and sizes), and protofilaments might explain the different mechanisms of epithelial transport that have been reported for different groups (Figure 9 ). Further experiments are neededt ot est 33-mer oligomers in the cellular context.
Conclusions and Perspectives
In the 1940s, the Dutch pediatrician Dr.D icke observed al ink between celiac disease (CD) and gluten consumption, and since then, the pathogenesis of CD has been widely studied.
However,e ven after all these years of efforts, crucial knowledge is still lacking about the early interaction of gliadin with the gut epithelium and, hence, the first steps in the pathogenesis of this autoimmune enteropathy.E ven more, the effects of gliadin in healthy individuals have not been systematically studied. The broad spectrum of responses with the gliadin digest and the more specific responses reported with the 20-mer,1 3-mer,a nd 33-mer peptides in different assays shows that gliadin protein contains immune and toxic fragments in its sequence. As mentioned, CD is characterized as aT h1-mediated autoimmune disease with high mucosal titers of interferon-g.A ss uch, the adaptive immune response that is triggered by gliadin has been extensively studied. However,r ecent data, discussed extensively in this Review,h ave shed light on the involvement of innate immunity in the host's early response to gluten.G liadina lone and the remaining large peptides (gliadin digest)a re highly immunogenic if exposed to different cell types. Moreover,ifitistaken into account that innate immunological responses elicited by gliadin are reported at pH 7.0, the hypothesis of colloidal assemblies of this protein as ar eal potential trigger,i nsteado fr andomlyd ispersed gliadin monomers, gains strength and may explain the reported immunogenicity of gliadin and its tissue stress effects. Likewise, the micellar aggregatesf ormed at pH 3.0 may be responsible for the inability of pepsin to cleave gliadin in smaller fragments efficiently.
Moreover,t he proteolytic resistance of the 33-mer and its self-assembly behavior on impaired cellular clearance conditions could explain the up-to-nowu nresolved question about the initial stages of gluten-related disorders in connection with Figure 8 . Spontaneous oligomerization of 33-mer dependsonpeptide concentration. On increasingthe peptide concentration,spherical-like oligomers undergo aconformational transition towards sheet-like structures with ap arallel b structure. [86, 87] ChemistryOpen 2018, 7,217 -232 www.chemistryopen.org It seems that the 33-mer gliadin fragment might be not only the immunodominant peptidei nC D, but also its accumulation and conformational transition towards the b-parallel structure might connectacommon food intolerance with conformational or amyloid diseases.
Recently,o ligomers of ar adiolabeled mutated 3 H-33-mer were found in blood plasma anda ccumulated in different organs in murinemodelsafter oral and intravenous administration. [96] These findings support the relevance of 33-mer oligomers in vivo. Research efforts are directed towards understanding the role of 33-mer aggregates in the context of the gut immune response. Moreover, considering the relevance of protein aggregates in disease, modulation/inhibition of the oligomerization process of the 33-mer may open new perspectives for the treatment of gluten-related diseases beyondt he gluten-freed iet. Figure 9 . The new pathogenic concept might involve the occurrence of 33-mer oligomerso na ccumulationc onditions. The molecular structure of the 33-mer gliadin peptide obtain by molecular dynamicsine quilibrium with its dimer (left). The different structures of the 33-mer (right), as characterized by transmission electron microscopy and scanning electronmicroscopy. [86] ChemistryOpen 2018, 7,217 -232 www.chemistryopen.org 2018 The Authors. Publishedb yWiley-VCH Verlag GmbH &Co. KGaA, Weinheim
